Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear Palsy
NCT03068468 is registered in ClinicalTrials.gov with Biogen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear Palsy
- Lead sponsor
- Biogen
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- June 1, 2017
- Completion date
- February 7, 2020
- Enrollment
- 490 (actual)
- Sites
- 86
Conditions
As the registry lists them; a condition with its own page is linked.